A Phase I Study of SIM0505 in Participants With Advanced Solid Tumors
This is an open-label, multicenter phase 1 study to evaluate the safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of SIM0505 in Adult Participants with Advanced Solid Tumors
Advanced Solid Tumors
DRUG: SIM0505 for injection|DRUG: SIM0505 for injection
dose escalation: Dose-limiting toxicity (DLT), At the end of Cycle 1 (each cycle is 21 days)|dose escalation: Adverse events (AEs), the whole dose escalation phase，an average of 2 year|dose optimization：Objective response rate (ORR), the whole dose optimization phase，an average of 1.5 year
This is an open-label, multicenter phase 1 study to evaluate the safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of SIM0505 in Adult Participants with Advanced Solid Tumors